Table 5 Descriptive statistics of the type and dose of cannabinoids and terpenoids in cannabis extracts based on perceived efficacy.

From: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community

Cannabinoids

Cannabis extracts perceived “effective” (N = 38)

Cannabis extracts perceived “ineffective” (N = 13)

N (Present)

Mean (SD) (mg/kg/day)

Range

N (Present)

Mean (SD) (mg/kg/day)

Range

CBD

37

1.23 (3.87)*

0–20.81

10

1.84 (5.20)*

0–18.7

THCA

36

0.56 (1.08)

0–4.97

13

0.62 (1.37)

0.004–3.9

CBDA

36

0.55 (1.58)

0–9.0

12

0.03 (0.06)

0–0.22

THC

38

0.39 (0.65)

0–3.12

12

0.40 (0.84)

0–2.7

CBC

38

0.24 (0.80)

0–4.74

10

0.03 (0.03)

0–0.1

CBN

32

0.04 (0.14)

0–0.86

8

0.02 (0.04)

0–1.16

CBGA

36

0.07 (0.14)

0–0.60

10

0.04 (0.13)

0–0.47

CBG

37

0.06 (0.10)

0–0.42

10

0.10 (0.32)

0–1.16

CBDVA

24

0.01 (0.05)

0–0.29

7

0.002 (0.004)

0–0.013

CBDV

19

0.01 (0.02)

0–0.08

7

0.003 (0.008)

0–0.03

THCV

35

0.01 (0.03)

0–0.11

8

0.007 (0.013)

0–0.05

Terpenoids

N (Present)

Mean (SD) (μg/kg/day)

Range

N (Present)

Mean (SD) (μg/kg/day)

Range

β-caryophyllene

36

50.6 (104)

0–497.9

11

23.5 (53.8)

0–182.4

caryophyllene oxide

29

13.5 (53.97)

0–329.5

10

4.5 (13.5)

0–49.2

β -myrcene

31

16.6 (33.6)

0–123.6

10

7.8 (21.8)

0–80

d-limonene

30

5.9 (10.3)

0–46.5

7

3.1 (8.2)

0–30

humulene

33

19.7 (37.4)

0–140.4

8

4.8 (11.5)

0–39.8

α-pinene

29

10.7 (21.5)

0–98.2

6

7.1 (20.1)

0–73

β-linalool

21

3.14 (7.45)

0–34.9

6

1.2 (2.6)

0–8

α-bisabolol

26

9.93 (30.4)

0–178

7

1.46 (4.09)

0–15

guaiol

23

4.97 (18.4)

0–112.2

6

0.4 (0.75)

0–2.11

β-pinene

27

3.26 (5.28)

0–18.02

8

2.23 (6.86)

0–25

nerolidol

25

3.3 (7.3)

0–31.9

7

1.68 (4.04)

0–14.32

terpinolene

17

2.34 (7.02)

0–37.8

6

0.05 (0.13)

0–0.48

camphene

6

0.11 (0.34)

0–1.56

5

0.19 (0.55)

0–2

ocimene

21

4.04 (12.06)

0–52.62

5

0.26 (0.69)

0–2.44

y-terpinene

8

0.62 (1.76)

0–8.68

4

0.02 (0.06)

0–0.21

p-cymene

8

0.34 (1.04)

0–4.59

4

0.59 (1.88)

0–6.79

3-carene

27

1.67 (5.29)

0–32.28

8

0.95 (1.68)

0–5.02

1-8-cineol

11

1.02 (3.96)

0–19.37

5

0.3 (0.71)

0–2.49

α-terpinene

8

0.33 (1.36)

0–8.28

5

0.03 (0.06)

0–0.05

geraniol

5

0.19 (0.59)

0–2.81

3

0.003 (0.005)

0–0.012

isopulegol

2

0.08 (0.28)

0–1.42

0

—

—

  1. Average dose of individual cannabinoids and terpenoids in 38 cannabis extracts perceived “effective” and 13 cannabis extracts perceived “ineffective” by the family in treating their child’s seizures.
  2. *Both datasets (perceived “effective” and “ineffective” group) each contained one 98% pure, pharmaceutical-grade CBD product that was being accessed legally via a government scheme. Excluding these two data points resulted in an average CBD dose of 0.69 ± 2.12 (range 0–12.3) mg/kg/day for perceived “effective” and 0.44 ± 1.26 (range 0–4.4) mg/kg/day for perceived “ineffective”. Presence in the cannabis extract sample was defined as >1 ng/mg for both cannabinoids and terpenoids.
Back to article page